DEF: Passage Bio Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance

Passage Bio is asking stockholders to approve a reverse stock split to boost its share price and maintain its Nasdaq listing.

Summary

• Passage Bio is holding its 2025 Annual Meeting of Stockholders virtually on May 28, 2025.
• The meeting will address the election of two Class II directors, ratification of KPMG LLP as the independent auditor, and a proposed amendment to the Restated Certificate of Incorporation to allow for a reverse stock split.
• The reverse stock split would be at a ratio between 1-for-5 and 1-for-50, with the exact ratio determined by the board of directors.
• The board seeks authorization to effect the reverse stock split to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• As of March 31, 2025, Passage Bio had 62,148,274 shares of common stock outstanding.
• The board of directors recommends voting FOR all proposals.

Sentiment

Score: 5

Explanation: The document is neutral in tone, presenting facts about the company's situation and the proposed actions. The need for a reverse stock split indicates underlying challenges, but the document focuses on the procedural aspects and potential benefits.

Positives

• The proposed reverse stock split aims to increase the marketability of the company's stock to institutional investors.
• A higher stock price could help attract and retain employees and other service providers.
• The reverse stock split will result in additional authorized and unissued shares becoming available for general corporate purposes.
• The board of directors believes that the decrease in the number of shares of our outstanding common stock because of the reverse stock split, and the anticipated increase in the price per share, would possibly promote greater liquidity for our stockholders with respect to their shares.

Negatives

• There is no guarantee that the reverse stock split will increase the stock price or maintain Nasdaq listing compliance.
• The stock prices of some companies that have effected reverse stock splits have subsequently declined, sometimes significantly, following their reverse stock splits.
• Liquidity may be adversely affected by the reduced number of shares that would be outstanding if the reverse stock split is effected, particularly if the price per share of our common stock begins a declining trend after the reverse stock split is effectuated.

Risks

• If the reverse stock split is not approved and the stock price does not increase to $1.00 per share, the company's common stock may be delisted from Nasdaq.
• Delisting could make it more difficult for investors to dispose of or obtain accurate quotations for the company's stock.
• Delisting could also subject the stock to penny stock regulations, imposing additional sales practice requirements on broker-dealers.
• The issuance of additional shares would be dilutive to our existing stockholders and may cause a decline in the trading price of our common stock.

Future Outlook

The company intends to effect the reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and is actively seeking additional capital to fund its operations.

Management Comments

• William Chou, M.D., President and Chief Executive Officer, signed the notice of the Annual Meeting.
• The board of directors believes that open communication between management and the board of directors is essential for effective risk management and oversight.

Industry Context

Many biotechnology companies face challenges in maintaining stock prices, especially during development phases. Reverse stock splits are a common strategy to meet listing requirements, but their success varies.

Comparison to Industry Standards

• The document references a peer group of twenty publicly traded companies in the biopharmaceutical industry used to evaluate executive compensation.
• The peer group reflected companies with the following characteristics: Publicly traded and listed on a major exchange; Primary business operations in the biotechnology or pharmaceutical industry; Completed an initial public offering prior to January 1, 2023; Does not currently generate revenues from the sale of marketed products; Market capitalization between $12 million and $105 million; Total full-time employee count between 20 and 150; and Last twelve months operating expenses between $30 million and $150 million.

Stakeholder Impact

• The reverse stock split could impact shareholders by potentially increasing the stock price and maintaining the Nasdaq listing.
• Delisting could negatively impact shareholders by making it more difficult to trade the stock.
• Employees and service providers may be affected by the company's ability to attract and retain talent based on the stock price.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on May 28, 2025.
• If approved, the board of directors will decide whether and when to implement the reverse stock split.
• The company must regain compliance with Nasdaq's minimum bid price requirement by July 27, 2025, to avoid delisting.

Key Dates

Keywords

reverse stock split, Nasdaq, minimum bid price, stockholders meeting, directors, KPMG, proxy statement, Passage Bio